GRPH Stock Price, Graphite Bio, Inc. Quote, Chart

Market Summary

USD15.87+0.02

Market Closed

0.13%

GRPH Alerts

Point72 Asset Management, L.P. reported owning 3.4% of GRPH [2024-03-25]

GRPH Stock Price

View Fullscreen

GRPH RSI Chart

GRPH Valuation

Market Cap

132.0M

Price/Earnings (Trailing)

-1.89

EV/EBITDA

-1.38

Price/Free Cashflow

-2.19

MarketCap/EBT

-1.88

GRPH Price/Earnings (Trailing)

GRPH Profitability

Return on Equity

-38.11%

Return on Assets

-99.42%

Free Cashflow Yield

-45.75%

GRPH Fundamentals

GRPH Earnings

Earnings (TTM)

-70.0M

Earnings Growth (Yr)

-51.61%

Earnings Growth (Qtr)

241.27%

Breaking Down GRPH Revenue

Last 7 days

-22.6%

Last 30 days

-28.8%

Last 90 days

-26.2%

Trailing 12 Months

-18.8%

How does GRPH drawdown profile look like?

GRPH Financial Health

Current Ratio

3.63

GRPH Investor Care

Buy Backs (1Y)

0.37%

Diluted EPS (TTM)

-7.22

Tracking the Latest Insider Buys and Sells of Graphite Bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2022	samsara biocapital, l.p.	bought	1,428,000	4.08	350,000	-
Apr 11, 2022	gutry phil	bought	20,050	4.01	5,000	chief business officer
Apr 11, 2022	samsara biocapital, l.p.	bought	303,068	4.07	74,464	-
Jan 24, 2022	samsara biocapital, l.p.	bought	200,100	8.7	23,000	-
Jan 21, 2022	samsara biocapital, l.p.	bought	899,000	8.99	100,000	-
Jan 20, 2022	samsara biocapital, l.p.	bought	384,497	8.92	43,105	-
Jan 19, 2022	samsara biocapital, l.p.	bought	504,181	9.24	54,565	-
Dec 15, 2021	samsara biocapital, l.p.	bought	227,533	10.19	22,329	-
Nov 22, 2021	samsara biocapital, l.p.	bought	2,047,100	10.15	201,685	-
Oct 15, 2021	samsara biocapital, l.p.	bought	28,727	12.49	2,300	-

Which funds bought or sold GRPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	3.00	302,593	3,736,070	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	68.97	65,768	149,540	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.41	1,809	36,494	-%
Feb 26, 2024	Virtu Financial LLC	new	-	91,000	91,000	0.01%
Feb 15, 2024	Legal & General Group Plc	unchanged	-	375	7,014	-%
Feb 15, 2024	BARCLAYS PLC	added	142	131,000	216,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	84,341	84,341	-%
Feb 15, 2024	Nantahala Capital Management, LLC	new	-	4,301,890	4,301,890	0.13%
Feb 14, 2024	Samsara BioCapital, LLC	unchanged	-	1,184,300	22,163,400	3.45%
Feb 14, 2024	STATE STREET CORP	reduced	-0.46	55,866	1,138,300	-%

Are Funds Buying or Selling GRPH?

Are funds buying GRPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GRPH

No. of Funds

GRPH Alerts

Point72 Asset Management, L.P. reported owning 3.4% of GRPH [2024-03-25]

Unveiling Graphite Bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	ecor1 capital, llc	4.8%	1,219,774	SC 13G/A
Mar 28, 2024	ra capital management, l.p.	16.6%	4,250,856	SC 13D
Mar 28, 2024	alpha wave ventures gp, ltd	14.1%	3,612,211	SC 13G
Mar 25, 2024	point72 asset management, l.p.	3.4%	864,942	SC 13G
Mar 25, 2024	versant venture capital vi, l.p.	8.2%	2,101,199	SC 13D/A
Mar 25, 2024	samsara biocapital, l.p.	4.7%	1,208,473	SC 13G/A
Feb 05, 2024	tang capital partners lp	5.4%	3,117,843	SC 13G
Feb 05, 2024	porteus matthew	6.1%	3,548,529	SC 13G/A
Nov 17, 2023	versant venture capital vi, l.p.	25.4%	14,708,398	SC 13D/A
Feb 14, 2023	samsara biocapital, l.p.	14.5%	8,459,314	SC 13G/A

Recent SEC filings of Graphite Bio, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	424B3	Prospectus Filed
Apr 10, 2024	EFFECT	EFFECT
Apr 09, 2024	S-1/A	Initial Public Offering
Apr 08, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	8-K	Current Report
Mar 29, 2024	S-1	Initial Public Offering
Mar 28, 2024	SC 13G	Major Ownership Report
Mar 28, 2024	SC 13D	13D - Major Acquisition
Mar 28, 2024	3	Insider Trading
Mar 25, 2024	4	Insider Trading

Peers (Alternatives to Graphite Bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-0.89%	-25.81%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	5.17%	-8.18%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-8.90%	-30.41%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-13.99%	-44.77%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-15.28%	57.81%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-11.84%	-2.48%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-11.98%	-22.42%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-3.94%	-8.31%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-12.98%	-52.88%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	7.90%	326.47%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-13.94%	-3.10%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	63.30%	36.92%	-0.25	2.14	-13.45%	66.37%

Graphite Bio, Inc. News

Latest updates

Graphite Bio, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-73.6%	70.00	266	287	310	47.00	335	354	379	402	416	387	-
Current Assets	-71.8%	67.00	239	251	270	47.00	298	327	344	382	401	385	21.00
Cash Equivalents	-80.8%	35.00	183	129	70.00	44.00	56.00	75.00	185	18.00	395	382	20.00
Net PPE	-99.6%	0.00	13.00	18.00	33.00	0.00	13.00	10.00	9.00	7.00	6.00	2.00	1.00
Liabilities	-68.3%	20.00	62.00	63.00	34.00	11.00	18.00	15.00	17.00	18.00	16.00	8.00	32.00
Current Liabilities	47.7%	19.00	13.00	12.00	14.00	9.00	14.00	12.00	13.00	12.00	11.00	8.00	32.00
Shareholder's Equity	-10.0%	184	204	224	276	296	316	338	361	384	400	379	-
Retained Earnings	72.3%	-95.20	-344	-321	-266	-25.28	-217	-193	-167	-141	-122	-107	-70.59
Additional Paid-In Capital	-99.5%	3.00	548	546	543	1.00	536	533	529	525	523	487	5.00
Shares Outstanding	17.6%	10.00	8.00	8.00	8.00	10.00	8.00	8.00	8.00	8.00	3.00	1.00	1.00
Float	-	-	-	151	-	66.00	-	150	-	-	-	817	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-72.9%	-16,250	-9,401	-13,655	-21,074	61,460	-22,217	-22,094	-21,240	-15,593	-15,415	-13,784	-8,060	-	-	-
Share Based Compensation	-420.5%	-6,926	2,161	2,845	3,263	-9,191	3,210	3,360	3,342	2,446	2,374	2,018	1,033	-	-	-
Cashflow From Investing	-427.0%	-208,885	63,875	72,226	43,163	255,350	3,496	-88,217	-170,666	-981	-3,636	-763	-360	-	-	-
Cashflow From Financing	1007100.0%	80,576	8.00	124	-8.00	29,909	-59.00	412	-	313	31,890	219,497	165,767	-	-	-

GRPH Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 32,137	$ 72,787
General and administrative	40,973	32,852
Restructuring and impairment costs	62,081	0
Total operating expenses	135,191	105,639
Loss from operations	(135,191)	(105,639)
Other income (expense), net:
Interest income, net	10,949	4,587
Loss on disposal of assets	(71)	0
Other expense, net	(338)
Total other income, net	10,540	4,587
Net loss	(124,651)	(101,052)
Unrealized gain (loss) on investments in marketable securities	1,048	(1,048)
Comprehensive loss	$ (123,603)	$ (102,100)
Net loss per share attributable to common stockholders-basic	$ (2.19)	$ (1.84)
Net loss per share attributable to common stockholders-diluted	$ (2.19)	$ (1.84)
Weighted-average shares used in computing net loss per share-basic	57,015,159	54,873,675
Weighted-average shares used in computing net loss per share-diluted	57,015,159	54,873,675

GRPH Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 184,259	$ 47,730
Investments in marketable securities, current	0	220,499
Restricted cash, current	1,602	0
Prepaid expenses and other current assets	2,160	7,136
Total current assets	188,021	275,365
Restricted cash	114	1,716
Investments in marketable securities, non-current	0	15,322
Property and equipment, net	0	22,630
Operating lease right-of-use assets	321	5,580
Other assets	0	1,289
Total assets	188,456	321,902
Current liabilities:
Accounts payable	250	2,608
Accrued compensation	1,534	3,799
Accrued research costs	0	720
Accrued expenses and other current liabilities	2,728	1,871
Operating lease liabilities, current	285	4,045
Total current liabilities	4,797	13,043
Operating lease liabilities, non-current	77	1,749
Other long- term liabilities	0	10,819
Total liabilities	4,874	25,611
Commitments And Contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized as of December 31, 2023 and 2022; and no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.00001 par value, 300,000,000 shares authorized as of December 31, 2023 and 2022; 58,008,396 and 58,221,760 shares issued and outstanding as of December 31, 2023 and 2022, respectively	1	1
Additional paid-in-capital	550,635	539,741
Accumulated other comprehensive loss	0	(1,048)
Accumulated deficit	(367,054)	(242,403)
Total stockholders' equity	183,582	296,291
Total liabilities and stockholders' equity	$ 188,456	$ 321,902

About Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

CEO	Ms. Kimberlee Cobleigh Drapkin CPA, CPA
WEBSITE	https://graphitebio.com
INDUSTRY	Biotechnology
EMPLOYEES	120

Graphite Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Graphite Bio, Inc.? What does GRPH stand for in stocks?

GRPH is the stock ticker symbol of Graphite Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Graphite Bio, Inc. (GRPH)?

As of Mon Apr 22 2024, market cap of Graphite Bio, Inc. is 131.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GRPH stock?

You can check GRPH's fair value in chart for subscribers.

What is the fair value of GRPH stock?

You can check GRPH's fair value in chart for subscribers. The fair value of Graphite Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Graphite Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GRPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Graphite Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether GRPH is over valued or under valued. Whether Graphite Bio, Inc. is cheap or expensive depends on the assumptions which impact Graphite Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRPH.